Emmanouil Damilakis

Mr. Emmanouil Damilakis


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EDEmmanouil Damilakis
Emmanouil Damilakis
Dimitrios MavrudisDimitrios Mavrudis
Dimitrios Mavrudis
MSMARIA SFAKIANAKI
MARIA SFAKIANAKI
John SouglakosJohn Souglakos
John Souglakos
Immunotherapy has considerably increased the number of anticancer agents in many tumor types including metastatic colorectal cancer (mCRC). Anti-PD-1 (programmed death 1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI) have been shown to benefit the mCRC patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, ICI is not effective in mismatch repair proficient (pMMR) colorectal tumors, which constitute a large population of patients. Several clinical trials evaluating the efficacy of immunotherapy combined with chemotherapy, radiation therapy, or other agents are currently ongoing to extend the benefit of immunotherapy to pMMR mCRC cases. In dMMR patients, MSI testing through immunohistochemistry and/or polymerase chain reaction can be used to identify patients that will benefit from immunotherapy. Next-generation sequencing has the ability to detect MSI-H using a low amount of nucleic acids and its application in clinical practice is currently being explored. Preliminary data suggest that radiomics is capable of discriminating MSI from microsatellite stable mCRC and may play a role as an imaging biomarker in the future. Tumor mutational burden, neoantigen burden, tumor-infiltrating lymphocytes, immunoscore, and gastrointestinal microbiome are promising biomarkers that require further investigation and validation.

25 February 2022 in International Journal of Public Health
Verified
Journal Article
Open access
EDEmmanouil Damilakis
Emmanouil Damilakis
Potential Positive Effects of COVID-19 on Cancer Care: A Window of Opportunity